Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition

被引:19
|
作者
Jin, Hyeon-Ok [1 ]
Lee, Yun-Han [2 ]
Park, Jin-Ah [1 ]
Kim, Jin-Hee [1 ]
Hong, Sung-Eun [3 ]
Kim, Hyun-Ah [4 ]
Kim, Eun-Kyu [4 ]
Noh, Woo Chul [4 ]
Kim, Byung-Hak [5 ]
Ye, Sang-Kyu [5 ]
Chang, Yoon Hwan [6 ]
Hong, Seok-Il [6 ]
Hong, Young-Joon [6 ]
Park, In-Chul [3 ]
Lee, Jin Kyung [1 ]
机构
[1] Korea Inst Radiol & Med Sci, KIRAMS Radiat Blood Specimen Biobank, Seoul 139709, South Korea
[2] Yonsei Univ, Dept Radiat Oncol, Coll Med, Seoul 120752, South Korea
[3] Korea Inst Radiol & Med Sci, Div Radiat Canc Res, Seoul 139706, South Korea
[4] Korea Inst Radiol & Med Sci, Dept Surg, Korea Canc Ctr Hosp, Seoul 139706, South Korea
[5] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea
[6] Korea Inst Radiol & Med Sci, Dept Lab Med, Korea Canc Ctr Hosp, Seoul 139709, South Korea
关键词
Akt; Bim; CHOP; mTOR; PI3K; Stat3; PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; RAPAMYCIN INHIBITOR; SIGNAL TRANSDUCER; CANCER; NVP-BEZ235; ACTIVATION; APOPTOSIS; PATHWAY; LEADS; PTEN;
D O I
10.1016/j.bbrc.2014.01.086
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The PI3K/Akt/mTOR axis in lung cancer is frequently activated and implicated in tumorigenesis. Specific targeting of this pathway is therefore an attractive therapeutic approach for lung cancer. However, non-small cell lung cancer cells are resistant to BEZ235, a dual inhibitor of PI3K and mTOR. Interestingly, blockage of Stat3 with a selective inhibitor, S3I-201, or siRNA dramatically sensitized the BEZ235-induced cell death, as evident from increased PARP cleavage. Furthermore, inhibition of Stat3 led to enhancement of cell death induced by LY294002, a PI3K inhibitor. Treatment of cells with a combination of BEZ235 and S3I-201 significantly induced the proapoptotic transcription factor, CHOP, and its targets, Bim and DR4. Knockdown of CHOP or Bim suppressed cell death stimulated by the combination treatment, implicating the involvement of these BEZ235/S3I-201-induced factors in pronounced cell death. Moreover, the BEZ235/S3I-201 combination enhanced TRAIL-induced cell death. Our results collectively suggest that blockage of Stat3 presents an effective strategy to overcome resistance to PI3K/Akt/mTOR inhibition. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:502 / 508
页数:7
相关论文
共 50 条
  • [11] MOLECULAR DETERMINANTS OF SENSITIVITY TO PI3K/AKT/mTOR PATHWAY INHIBITION IN GLIOBLASTOMA
    von Achenbach, Caroline
    Weller, Michael
    Kaulich, Kerstin
    Gramatzki, Dorothee
    Zacher, Angela
    Fabbro, Doriano
    Reifenberger, Guido
    Szabo, Emese
    NEURO-ONCOLOGY, 2018, 20 : 48 - 48
  • [12] Combined Inhibition of PI3K and STAT3 signaling effectively inhibits bladder cancer growth
    Peng, Weidong
    Zhang, Haojie
    Yin, Mingwei
    Kong, Dejie
    Kang, Liping
    Teng, Xinkun
    Wang, Jingjing
    Chu, Zhimin
    Sun, Yating
    Long, Pengpeng
    Cui, Chengying
    Lyu, Bin
    Zhang, Jinzhi
    Xiao, Han
    Wu, Mingqing
    Wang, Yongqiang
    Li, Yang
    ONCOGENESIS, 2024, 13 (01):
  • [13] Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells
    Kawin Leelawat
    Siriluck Narong
    Wandee Udomchaiprasertkul
    Surang Leelawat
    Sumalee Tungpradubkul
    Cancer Cell International, 9
  • [14] Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells
    Leelawat, Kawin
    Narong, Siriluck
    Udomchaiprasertkul, Wandee
    Leelawat, Surang
    Tungpradubkul, Sumalee
    CANCER CELL INTERNATIONAL, 2009, 9
  • [15] Curcumin Suppresses Vasculogenic Mimicry Capacity of Hepatocellular Carcinoma Cells through STAT3 and PI3K/AKT Inhibition
    Chiablaem, Khajeelak
    Lirdprapamongkol, Kriengsak
    Keeratichamroen, Siriporn
    Surarit, Rudee
    Svasti, Jisnuson
    ANTICANCER RESEARCH, 2014, 34 (04) : 1857 - 1864
  • [16] Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma
    Frank Eckerdt
    Jessica Clymer
    Jonathan B. Bell
    Elspeth M. Beauchamp
    Gavin T. Blyth
    Stewart Goldman
    Leonidas C. Platanias
    Scientific Reports, 9
  • [17] Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma
    Eckerdt, Frank
    Clymer, Jessica
    Bell, Jonathan B.
    Beauchamp, Elspeth M.
    Blyth, Gavin T.
    Goldman, Stewart
    Platanias, Leonidas C.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [18] Dual PI3K and mTOR Inhibition in Waldenstrom Macroglobulinemia
    Husu, E. N.
    Roccaro, A. M.
    Anderson, K. C.
    Ghobrial, I. M.
    Leleu, X.
    Sacco, A.
    Melhem, M. R.
    Azab, A. K.
    Jia, X.
    Ngo, H. T.
    Azab, F.
    Runnels, J.
    Quang, P.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S144 - S145
  • [19] Resistance Mechanisms to PI3K-mTOR Inhibition in NSCLC
    Moore, Gillian
    Heavey, Susan
    O'Byrne, Kenneth
    Finn, Stephen
    Cuffe, Sinead
    O'Neill, Michael
    Gately, Kathy
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1277 - S1278
  • [20] Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells
    Chen, Bin
    Xu, Xin
    Luo, Jie
    Wang, Heyong
    Zhou, Songwen
    PLOS ONE, 2015, 10 (06):